Kewal Handa

Handa has been appointed non-executive chairman and part-time non-official director as per a notification of the finance ministry, the lender said in a BSE filing.

'Continuous innovation must to stay ahead of competition'

Watch the discussion led by CNBC-TV18's AB Ravi with Jitesh Bhatt, Founder, Jasodha Clinic and Amit Tiwari, MD and CEO of MKT Softwares in which they were guided and mentored by Kewal Handa, Chairman, Salus Lifecare and Ajay Thakur Head, BSE SME Exchange on how to overcome hurdles and scale up their businesses.

Won't be ethical for pharmas to bring back banned drugs: Expert

The government had banned the FDC medicines including popular names like Corex cough syrup, Vicks and D-cold on March 10 terming them a 'risk' to humans.

SME Exchange: Mentoring passionate entrepreneurs

CNBC-TV18 and BSE together are hosting this mentoring series SME Exchange. The underlying objective of this series is to guide and advise passionate entrepreneurs on how to overcome the hurdles like raising money, people skill, technology or marketing.

India Healthcare Awards 15-16: Jury at work

Watch India Healthcare Awards 2015-2016 Jury round where the eminent jury of the India Healthcare Awards met to pick the winners out of the shortlisted hospitals.

Experts divided on benefits of easing FDI in brownfield pharma

Kewal Handa, Former MD, Pfizer believes easing of FDI up to 74 percent for the brownfield projects would see more MNCs coming into India and more mergers and acquisitions in the sector.

Indian pharma cos need to step-up safeguards at plants: Handa

In the last five months, plants of nine Indian pharmaceutical companies - Cipla, Dr Reddy‘s, Sun Pharma, Cadila, Lupin and Natco Pharma.- have come under the US Food and Drug Administration (FDA) scanner.

Experts discuss agenda for new govt beyond Budget 2014

An expert panel consisting Rashesh Shah, Chairman and CEO of the Edelweiss Financial Services Group, Kewal Handa, Former Managing Director of Pfizer India and Piruz Khambatta, Chairman Private limited discuss the agenda for the government beyond Budget 2014‘s hits and misses on ‘Change India‘s second episode.

Here's who competed for the coveted India Healthcare Awards

India is all set to become one of the top economies of the world and Asia‘s next super power. India‘s growing market of 1.2 billion people with an average age of 25 an economy capable of generating a GDP of 8.5% and a middle-class of 250 million people have experts‘ confidence that India will grow rapidly in coming decade.

More clarity needed on non-compete clause: Medybiz

The department of industrial policy and promotion (DIPP) today notified the new FDI policy for the pharma sector. The new policy retains old norms of keeping the FDI cap at 100 % for the sector.

Post stake buy, GSK may eye acquisition

After the UK parent of GlaxoSmithKline Pharmaceutical announced an open offer to increase its stake from 50.3 percent to 75 percent at a cost of Rs 6,400 crore, CNBC-TV18 spoke with an industry veteran, Former Pfizer India MD Kewal Handa to get his views.

Pfizer plans to launch 15 new products in FY13

Pharma major Pfizer registered a net profit of Rs 48.10 crore in the fourth quarter of FY12 in comparison to Rs 63.14 crore in the corresponding quarter last fiscal.

Pfizer's India MD Kewal Handa to retire in August

Under Handa''s leadership Pfizer India entered the branded generics market and grew in strength by mergers with Parke-Davis and Pharmacia and integration with Wyeth India, the company said.

GoM vs pharma industry: Battling for market driven pricing

The pharma industry is on the edge of its seat with all eyes on the April 4 Group of Ministers (GoM) meeting which will decide on a final pricing policy for essential drugs, reports CNBC-TV18's Archana Shukla.

Pharma sector moots market-based pricing: Pfizer

In an interview to CNBC-TV18, Kewal Handa, managing director of Pfizer and Vikas Dandekar, India Bureau Chief of PharmAsia News.Com discuss the issue of drug pricing.

Union Budget 2012: Pharma pins hopes on FM

While dealing with fiscal challenges is likely to be the FM's core focus this Budget, the pharma industry, on its part, hopes that Pranab Mukherjee will also look into some of their long standing demands. CNBC-TV18’s Swathi Narayanan and Archana Shukla report on the pharma and healthcare sectors' wishlist for Budget 2012.

Govt needs to relook at draft pharma pricing policy: Pfizer

Speaking to CNBC-TV18, Kewal Handa, managing director of Pfizer said, the draft NPPP has a few positives but the government needs to re-look at it altogether.

Govt's draft National Pharma Pricing Policy find few takers

The government's aim to regulate prices of all 348 essential drugs in the country is not going well with the Indian pharma industry.

CCI's role key in pharma FDI; FIPB not best option: Pfizer

The Arun Maira committee report on pharma FDI was accepted by the government which said the CCI should be entrusted with the task of scrutinising pharma FDI in brownfield projects. Kewal Handa, Country Manager at Pfizer India tells CNBC-TV18 feels it is just going back to the old regime of FIPB.

Have multiple launches planned in 2011, says Pfizer

Speaking to CNBC-TV18, Kewal Handa, MD of Pfizer said the firm has planned multiple launches in 2011. "We expect to grow above market rates," he added.